Edgewell Personal Care Q1 loss widens; Feminine Care sold for $340 million
Edgewell reported first-quarter fiscal 2026 results with continuing-operations net sales of $422.8 million, up 1.9%, but a wider loss of $0.63 per diluted share from continuing operations versus $0.21 a year earlier. The company also completed the sale of its Feminine Care business for $340 million and now reports its outlook on a continuing-operations basis, which shows lower adjusted EPS and EBITDA ranges than the prior consolidated outlook because Feminine Care is removed.
Key points
- Continuing-operations net sales were $422.8 million, up 1.9%; organic net sales decreased 0.5%.
- Adjusted EPS was $(0.16) versus $(0.10) a year earlier; GAAP loss per diluted share was $(0.63) from continuing operations and $(1.41) including discontinued operations.
- Fiscal 2026 adjusted EPS outlook is $1.70 to $2.10 on a continuing basis, versus $2.15 to $2.55 previously; the company says the full-year outlook for continuing operations is unchanged from its prior outlook.
- Expected pre-tax restructuring and related charges for fiscal 2026 rose to approximately $65 million from $49 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 09, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.